research use only
Cat.No.S8219
| Related Targets | Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) |
|---|---|
| Other GlyT Inhibitors | Iclepertin |
|
In vitro |
DMSO
: 100 mg/mL
(184.0 mM)
Ethanol : 100 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 543.46 | Formula | C21H20F7N3O4S |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 845614-11-1 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | RG1678, RO-4917838 | Smiles | CC(C(F)(F)F)OC1=C(C=C(C=C1)S(=O)(=O)C)C(=O)N2CCN(CC2)C3=C(C=C(C=N3)C(F)(F)F)F | ||
| Targets/IC50/Ki |
GlyT1
(in cells stably expressing mGlyT1b) 22 nM
GlyT1
(in cells stably expressing hGlyT1b) 25nM
|
|---|---|
| In vitro |
RG1678 noncompetitively inhibits [3H]glycine uptake in cells stably expressing hGlyT1b and mGlyT1b, with IC50 values of 25 ± 2 nM and 22 ± 5 nM, respectively (n = 6) and competitively displaces [3H]ORG24598 binding with a Ki of 8.1 nM at human hGlyT1b in membranes from Chinese hamster ovary cells. RG1678 has no effect on hGlyT2-mediated [3H]glycine uptake up to 30 μM concentration. There is no significant species difference in the pharmacology for RG1678 based on the ability of the compound to displace [3H]ORG24598. In hippocampal CA1 pyramidal cells, RG1678 enhances NMDA-dependent long-term potentiation (LTP) at 30 nM (213 ± 18%; n=7), 100 nM (269 ± 44%, n=13) but not at 300 nM (152 ± 14%; n = 9).
|
| In vivo |
Administration of RG1678 produces a long-lasting (>3h) dose-dependent increase in extracellular glycine levels both in microdialysis experiments conducted in rats and CSF of rats. In mice, RG1678 dose-dependently and significantly attenuates hyperlocomotion induced by the psychostimulant D-amphetamine. RG1678 also prevents the hyper-response to D-amphetamine challenge in rats treated chronically with phencyclidine, an NMDA receptor open-channel blocker.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05883748 | Enrolling by invitation | Erythropoietic Protoporphyria |
Disc Medicine Inc |
August 31 2023 | Phase 2|Phase 3 |
| NCT05828108 | Recruiting | Steroid-refractory Diamond-Blackfan Anemia (DBA) |
National Heart Lung and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) |
July 25 2023 | Phase 1|Phase 2 |
| NCT05308472 | Active not recruiting | Erythropoietic Protoporphyria |
Disc Medicine Inc |
October 31 2022 | Phase 2 |
| NCT03271541 | Completed | Beta-Thalassemia |
Hoffmann-La Roche |
October 26 2017 | Phase 2 |
| NCT02019290 | Withdrawn | Healthy Volunteer |
Hoffmann-La Roche |
February 10 2014 | Phase 1 |
| NCT01674361 | Completed | Obsessive-Compulsive Disorder |
Hoffmann-La Roche |
December 31 2012 | Phase 2 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.